Formulation and evaluation of mini-tablets-filled-pulsincap delivery of lornoxicam in the chronotherapeutic treatment of rheumatoid arthritis

Pakistan Journal of Pharmaceutical Sciences

Volumn 28, Issue 1, 2015, Pages 185-193

  Hadi, Mohd Abdul ^a   Rao, Nidagurthi Guggilla Raghavendra ^b   Rao, Avanapu Srinivasa ^a  

^a Bhaskar Pharmacy College   (India)

^b Jyothishmathi Institute of Pharmaceutical Science   (India)

Author keywords

Chronotherapeutic pattern; Lonoxicam; Mini tablets; Pulsincap formulation; Rheumatoid arthritis

Indexed keywords

ALGINIC ACID; LORNOXICAM; ANTIRHEUMATIC AGENT; GLUCURONIC ACID; HEXURONIC ACID; HYDROXYPROPYLMETHYLCELLULOSE; PIROXICAM; POWDER; TABLET;

ARTICLE; CHRONOTHERAPY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; ENTERIC COATED TABLET; IN VITRO STUDY; INFRARED SPECTROSCOPY; MINITABLET FILLED PULSINCAP; PHYSICAL CHEMISTRY; PREFORMULATION; RHEUMATOID ARTHRITIS; TABLET COMPRESSION; TABLET DISINTEGRATION; TABLET HARDNESS; TABLET THICKNESS; ANALOGS AND DERIVATIVES; ARTHRITIS, RHEUMATOID; CHEMISTRY; HUMAN; KINETICS; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; POWDER; SOLUBILITY; TABLET;

ADMINISTRATION, ORAL; ALGINATES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG CHRONOTHERAPY; DRUG STABILITY; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; HYPROMELLOSE DERIVATIVES; KINETICS; PIROXICAM; POWDERS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TABLETS;

EID: 84920554601     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Abanesh Kumar Bansal and Vishal Deshpande (2013). Development and evaluation of dual cross-linked pulsatile beads for chronotherapy of rheumatoid arthritis. J. Pharm., 1-8.
2. Anamika Singh, Harikesh Dubey, Indu Shukla, Dharmchand P and Singh (2012). Pulsatile drug delivery System: An approach of medication according to Circadian Rhythm. J. App. Pharm. Sci., 2(3): 166-176.
3. Arvidson NG, Gudbjornsson B, Elfman L, Ryden AC, Totterman TH and Hallgren R (1994). Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann. Rheum. Dis., 53: 521-524.
4. Aulton M (2000). Phamaceutics: The science of dosage form design. Churchill Livingston, Edinburgh, pp.15-32.
5. Bechard SR and Leroux (1992). Coated pelletized dosage form: Effect of compaction on drug release. Drug Dev. Ind. Pharm., 18: 1927-1944.
6. Carla Lopes M, Jose Manual Souza lobo, Jaao Pinto F, Paulo and Costa (2006). Compressed Mini-tablets as a biphasic delivery system. Int. J. Pharm., 323: 93-100.
7. Cha J, Gilmor T, Lane P and Ranweiler JS (2001). Stability studies in handbook of modern pharmaceutical analysis. Separation Science and Technology. Elsevier, pp.459-505.
8. Chu KR, Lee E, Jeong SH and Park ES (2012). Effect of particle size on the dissolution behaviors of poorly water-soluble drugs. Arch. Pharm. Res., 35(7): 1187-1195.
9. Frank and Buttgereit (2011). Chronotherapy with Glucorticoids in Rheumatoid Arthritis. The Rheumatologist., January. Available a http://www.therheumatologist. org/details/article/984173/Chronotherapy-with-Glucorticoids-in-Rheumatoid-Arthritis.html
10. Gang C, Feng A, Mei-Juan Z and Jin S et al., (2004). Time and pH-dependentcolon-specific drug delivery for orally administered diclofenac sodium and 5-amino salicylic acid. World J. Gastroenterol., 10: 1769-1774.
11. Gothaskar AV, Joshi AM and Joshi NH (2004). Pulsatile drug delivery system-a review. Drug Del. Tech., 4(5): 1-14.
12. Hong Wen and Kinam Park (2011). Oral controlled release formulation design and drug delivery: Theory to Practice. Wiley Publishers., pp.118-119.
13. ICH Guidelines (2003). Stability testing of new drug substances and products. Q1A(R2): 1-20.
14. Kidd B and Frenzel W (1996). A Multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis, J. Rheumatol., 23: 1605-1611.
15. Krishainah YSR and Satyanarayan S (2001). Colonspecific drug delivery system. In: Jain NK, editor. Advances in controlled and noveldrug delivery. 1st Ed., CBS publishers and distributors, New Delhi, India, pp.89-119.
16. Leon Lachman and Herbert Lieberman A (2009). The theory and practice of Industrial Pharmacy. Special Indian edition, pp.293-373.
17. Mastiholimath VS, Dandagi PM, Samata Jain S, Gadad AP and Kulkarni AR (2007). Time and pH dependent colon specific, pulsatile delivery of theophylline for nocturnal asthma. Int. J. Pharm., 328: 49-56.
18. Maurizio Cutolo (2012). Rheumatoid Arthritis Chronotherapy. Eu. Mus. Ske. Rev., 7(1):29-32.
19. Meena A, Kumar B, Suriya Prakash TNK and Senthamarai R (2011). Development and evaluation of pulsatile drug delivery system of lornoxicam. Int. J. Pharm. World Res., 2(2): 1-15.
20. Merck (1996), The Merck index, Merck Research laboratories, White house station, NJ, USA, pp.5582.
21. Mohd Abdul Hadi and Raghavendra Rao NG (2012). Novel techniques in formulations: An Overview. World J. Pharm. Res., 1(3): 1-17.
22. Mohd Abdul Hadi, Raghavendra Rao NG and Sunil Firangi (2012). Mini-tablets technology: An Overview. Am. J. Pharm. Res., 2(2): 128-150.
23. Noorana tehseen, Vinay rao and Mohd abdul hadi (2013). Design and characterization of twice-daily mini-tablets formulation of pregabalin. Int. J. Pharm. Pharm. Sci., 5(1): 168-175.
24. Puniya supriya, Bala rajni and Rana AC (2012). Pelletization techniques: A Literature review. Int. Res. J. Pham., 3(3): 43-47.
25. Rainer F, Klein G and Mayrhofer F (2006). A prospective, multi centre, open-label, uncontrolled Phase II study of the local tolerability, safety and efficacy of intramuscular chlortenoxicam in patients with acute low back pain. Eur. J. Clin. Res., 8: 1-13.
26. Sindhu, Abraham and Srinath MS (2007). Development of modified pulsincap drug delivery system of metronidazole for drug targeting. Ind. J. Pharm. Sci., 69(1): 24-27.
27. Survase S and Kumar N (2007). Pulsatile drug delivery: Current Scenario, CRIPS, 8: 27-33.
28. Zahirul Khan MI, Zeljko P and Nevenka K (1999). A pHdependent colon targeted oral drug delivery system using methacrylic acid copolymers. Manipulation of drug release using Eudragit® L100-55 and Eudragit® S100 combinations. J. Contr. Rel., 58: 215-222.
29. Zhang Y, Zhong D, Si D, Guo Y, Chen X and Zhou H (2005). Lornoxicam Pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br. J. Clin. Pharmacol., 59: 14-17.